Trial Profile
A Phase I / IIa trial evaluating safety and efficacy of bacteriophages specifically designed to treat inflammatory bowel diseases (IBD)
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 19 Feb 2018
Price :
$35
*
At a glance
- Drugs Bacteriophages (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; Therapeutic Use
- 19 Feb 2018 New trial record
- 15 Feb 2018 According to an Intralytix media release, the company has received clearance from the Food and Drug Administration (FDA) to initiate Phase I / IIa clinical trials at Mount Sinai hospital in New York.